Exact Sciences Corp. has initiated legal proceedings against Geneoscopy Inc., alleging infringement on a patent related to its Cologuard stool DNA-based colorectal cancer screening test. The biotech corporation asserts that its competitor illicitly practices a patent that protects its innovative screening test, and has consequently requested the court to prohibit the competing test from reaching the market.
This lawsuit further intensifies the rivalry within the industry, as companies strive to establish their hold on potentially life-saving technologies and maintain their competitive edges. The accused, Geneoscopy Inc., has yet to publicize any response to the allegations. The court’s decision may indeed bear significant implications not just for the two corporations involved, but also for the landscape of colorectal cancer screening and the broader healthcare market.
For more detailed insights into the lawsuit, you may refer to the reporting by Kelly Lienhard on Law360.